Bladder Cancer
| Year | Contributions in Treatment and Research |
|---|---|
| 1943-1949 | Techniques of Radical Cystectomy and Pelvic Lymphadenectomy |
| 1952 | Myron Melamed Describes Carcinoma-In-Situ of the Urothelium |
| 1956 | Technique of Urethrectomy |
| 1959 | Preoperative Irradiation and Radical Cystectomy |
| 1973 | Technique of In-Continuity Urethrectomy during Radical Cystectomy |
| 1974 | Outpatient Cystoscopy and Fulguration of Recurrent Superficial Papillary Bladder Tumors |
| 1975 | Identification and Characterization of Tumor-Associated Antigens |
| 1979 | Diagnostic Value of Urinary Cytology and Flow Cytometry |
| 1979-1984 | Intravesical Bacillus Calmette-Guérin (BCG) for Superficial Bladder Tumors and Randomized Trials of BCG, used for FDA Approval |
| 1981 | Ureteroscopic Destruction of Upper Tract Tumors |
| 1983 | Neoadjuvant MVAC Chemotherapy and Radical Cystectomy |
| 1983-1992 | MVAC Chemotherapy Cures Transitional Cell Carcinoma |
| 1983-1995 | Bladder-Sparing Strategies for Invasive Bladder Cancer |
| 1989 | Prognostic Significance of Lewis Blood Group Antigen |
| 1989-1999 |
G-CSF Effective with M-VAC Chemotherapy Prognostic Factors Identified |
| 1992-1999 | Molecular Analysis (Rb, p53, mdm22, p16, p21, INK4A) |
| 1995-1999 | ITP Chemotherapy Improves Survival, and Post-Chemotherapy Surgery Found Beneficial |
| 1997 | New Staging for Bladder Cancer (Generated by Memorial Sloan Kettering’s Urology Service and Department of Pathology) Adopted by AJCC/UICC |
| 2003-2005 |
Defined Survival Benefit Related to the Quality of the Pelvic Lymph Node Dissection in Patients Undergoing Radical Cystectomy Defined Refractory Carcinoma-In-Situ |
| 2006 | Established an Outcomes Nomogram for Bladder Cancer Patients Undergoing Radical Cystectomy |
| 2007-2009 | Described the Treatment Paradigm Shift in Management of T1 Bladder Cancer |
| 2008 | Established Pathologic Concerns for Prostate-Sparing Radical Cystectomy Helped to Establish Role of Gemcitabine and Cisplatin in the Neoadjuvant Management of Muscle-Invasive Bladder Cancer |
| 2009 | Comprehensively Established Morbidity Associated with Radical Cystectomy and Urinary Diversion |
| 2010 | Documented Role of Minimally Invasive Surgical Techniques in the Management of Upper Tract Transitional Cell Carcinoma |
| 2012 | Established the Genomic Characteristics of Bladder Cancer That Will Allow for Targeting Therapy More Effectively in Bladder Cancer Patients Data Validating Updated TNM Staging of LN for Bladder Cancer Patients |
Prostate Cancer
| Year | Contributions in Treatment and Research |
|---|---|
| 1950-1960 | Ablative Surgery Adrenalectomy Exenteration for Locoregional Cancers |
| 1970 | Whitmore Staging System (AJCC) Technique of Retropubic I-125 Implantation Natural History Defined |
| 1974 | Flutamide Polyamine |
| 1993 | Prostate-Specific Monoclonal Antibodies (PSMA) Cloning of PSMA Gene Neoadjuvant Hormonal Therapy and Radical Prostatectomy Three-Dimensional Conformal Radiation Therapy with Intensity Modulation |
| 1995 | Flutamide Withdrawal Syndrome |
| 1999 | Prognostic Nomograms Nerve Grafts with Radical Prostatectomy Quality of Life, Utility Assessment |
| 2004-2006 | Surgeon as an Independent Predictor of Outcomes |
| 2007-2010 | Describe Surgical Learning Curve for Radical Prostatectomy |
| 2007-2012 | Established Indications for Standard vs Limited Pelvic Lymph Node Dissection |
| 2010 | Completed First Comprehensive Genomic Analysis of Prostate Cancer Comprising a Wide Spectrum of the Disease across Multiple Platforms |
Testis Cancer
| Year | Contributions in Treatment and Research |
|---|---|
| 1960 | Technique of Retroperitoneal Lymph Node Dissection |
| 1972-7980 | Cisplatin-Based Combination Chemotherapy VAB-I through VAB-VI Protocols Hydration for High-Dose Cisplatin Chemotherapy Salvage Surgery Post-Chemotherapy Adjuvant Chemotherapy |
| 1979 | Surveillance for Stage I Nonseminomatous Germ Cell Testis Tumors |
| 1983 | Risk-Adjusted Treatment Strategies Salvage Chemotherapies |
| 1988 | Marker Gene I(12)p |
| 1997 | Staging System Incorporating Tumor Markers Defined Mechanism of TP53 Mutations and Resistance |
| 1998 | Management of Teratoma with Secondary Somatic Malignancy |
| 2000 | TIP for Second-Line Chemotherapy |
| 2003 | Integration of Markers Status in Clinical Decision Making for Patients with Low-Stage Non-Seminomatous Germ Cell Testis Tumors |
| 2007 | High-Dose TICE for Salvage Chemotherapy |
| 2007 | Implications of Modified Templates in Low-Stage and Advanced Non-Seminomatous Germ Cell Testis Tumors — Bilateral Infrahilar Is the Gold Standard |
| 2009 | Nerve-Sparing Retroperitoneal Lymph Node Dissection following Chemotherapy |
| 2010 | Impact of Total Number of Lymph Nodes Resected on Clinical Outcome |
| 2021 | First CLIA and State Department of Health (NY) Approval for MSK miRNA Assay (MMA) |
| 2022 | Full accrual of “TIGER” Trial (High-Dose Chemotherapy vs TIP) |
Renal Cancer
| Year | Contributions in Treatment and Research |
|---|---|
| 1949 | Technique of Radical Nephrectomy |
| 1975 | Tumor Vaccine Developed Monoclonal Antibodies |
| 1979 | Partial Nephrectomy in Patients with Normal Contralateral Kidney |
| 1997 | Histologic and Molecular Genetic Classification |
| 1998 | Randomized Trials of Cis-Retinoic Acid ± Interferon |
| 1997-2000 | Prognostic Factors and Nomogram |
| 2006 | Partial Nephrectomy Prevents Chronic Kidney Disease |
| 2007-2012 | Establishment of Clear Cell Renal Carcinoma-Specific ImmunoPET Scan (G250) |
Penile and Urethral Cancer
| Year | Contributions in Treatment and Research |
|---|---|
| 1956 | Technique of Radical Groin Dissection |
| 1983 | Extended Radical Excision (Pubectomy, Emasculation) |
| 1994 | Described Myocutaneous Flap Coverage following Massive Groin Dissection with Skin Loss |
| 1996 | Risk Stratification for Invasive Penile Cancer |
| 2001 | Management of Genitourinary Melanoma Described |
| 2006 | Sentinel Lymphoscintigraphy Utilized in Penile Carcinoma and Melanoma |